25.01.2017
WILEX AG DE000A11QVV0
DGAP-News: WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement
DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies
of the Max Delbrück Center and Signs License Agreement
25.01.2017 / 11:02
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies
of the Max Delbrück Center and Signs License Agreement
Munich, Germany, 25 January 2017 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FWB)
today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg,
Germany, signed the license agreement with the Max Delbrück Center for
Molecular Medicine in the Helmholtz Association (MDC) in Berlin covering
BCMA antibodies. The license agreement follows an option agreement signed
in September 2016.
Financial details are confidential but will not have a material impact on
WILEX' cash reach.
As a result of a selection and optimization process of the BCMA antibodies,
the ATAC candidate HDP-101 was selected and is currently being prepared for
clinical development that could start by the end of 2018.
Related releases
24 January 2017: Am MDC entwickelte Tumor-Antikörper gegen Knochenmarkkrebs
gehen in die Anwendung (in German only)
19 September 2016: WILEX AG: Subsidiary Heidelberg Pharma Signs Option
Agreement with Max Delbrück Center
About Max Delbrück Center
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association
(MDC) was founded in January 1992 on the recommendation of the German
Council of Science and Humanities ("Wissenschaftsrat") with the goal of
linking basic science to clinical research. It was named for Max Delbrück,
a physicist, biologist, and Nobel Prize winner. Currently the institute
employs more than 1600 people from nearly 60 countries; over 1300 of those
are directly involved in research. The MDC's annual budget is over 80
million Euros, along with substantial third-party funding obtained by
individual scientific groups. As is the case with all Helmholtz institutes,
the MDC receives 90 percent of its funding from the federal government and
10 percent from Berlin, the state where it resides.
About Heidelberg Pharma's proprietary ATAC technology
Antibody drug conjugates (ADCs) combine the high affinity and specificity
of antibodies with the potency of cytotoxic small molecules for the
treatment of cancer and inflammatory diseases. ATACs are ADCs that are
bound to highly potent amatoxin molecules. Amatoxins are small bicyclic
peptides naturally occurring in the death cap mushroom. They inhibit mRNA
transcription by binding to RNA polymerase II, a mechanism that is crucial
for the survival of eukaryotic cells. In preclinical testing, ATACs have
been shown to be highly efficacious, overcoming frequently encountered
resistance mechanisms and combatting even quiescent tumor cells.
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company based in Munich, Germany, that
serves as a parent and holding company. The Company's research and
development work is conducted by its subsidiary Heidelberg Pharma GmbH in
Ladenburg. Heidelberg Pharma is the first company to develop the toxin
Amanitin into cancer therapies using its proprietary Antibody Targeted
Amanitin Conjugate (ATAC) technology and to advance the biological mode of
action of the toxin as a novel therapeutic principle. This proprietary
technology platform is being applied to develop the company's own
therapeutic ATACs as well as in third-party collaborations to create a
variety of ATAC candidates. The proprietary lead candidate is a BCMA ATAC
for multiple myeloma. WILEX's clinical assets MESUPRON(R) and REDECTANE(R)
have been partnered, while RENCAREX(R) is available for out-licensing and
further development. WILEX is listed on the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at
www.wilex.com
Contact IR/PRsupport WILEX AG MC Services AG Sylvia Wimmer Katja Arnold (CIRO) Corporate Communications Managing Director & Partner Tel.: +49 (0)89-41 31 38-29 Tel.: +49 (0)89-210 228-40 Email: investors[at]wilex.com Mobile: +49 (0)160 9360 3022 Grillparzerstr. 18, 81675 Email: katja.arnold[at]mc-services.eu Munich, GermanyThis communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward- looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------------- 25.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 18 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 538993 25.01.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
WILEX AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6